{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fdealbook-podcast.simplecast.com%2Fepisodes%2F20241205-8-bFQYq2eN","width":444,"version":"1.0","type":"rich","title":"How Anti-Obesity Drugs are Redefining Pharma and Wellness with David Ricks and Fatima Cody Stanford","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/4105a47a-42e5-4ccc-887a-832af7989986/292a39a3-013c-49da-916d-e57a8c5a8b66/nyt-db-3000px.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/8501f65c-c745-4545-9da5-13450befadaa\" height=\"200\" width=\"100%\" title=\"How Anti-Obesity Drugs are Redefining Pharma and Wellness with David Ricks and Fatima Cody Stanford\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions.\n\nDavid Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how the drug could potentially be used to treat alcohol use disorder or other addictions."}